
    
      Eligible patients will ask to participate after oral and written information. Evaluation of
      walking capacity (self reported and treadmill measured), co-morbid condition and quality of
      life (WELCH, SF-36, Edinburg) will be performed at inclusion, after the first dose and at 3
      months of oral treatment through sildenafil 100mg/day or placebo from inclusion to 3 months.

      Indication for revascularisation will be evaluated at 3 months according to symptoms and
      walking capacity according to the Rutherford classification.

      Primary endpoint is the proportion of patients showing either a fatal events (cardio-vascular
      or noncardiovascular) or hospitalisation for non fatal cardiovascular events at 6 and 9
      months follow up from inclusion.
    
  